The stock of Denali Therapeutics Inc (NASDAQ: DNLI) has increased by 0.33 when compared to last closing price of 21.18. Despite this, the company has experienced a 4.27% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-09 that Denali Therapeutics Inc.’s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali’s stock remains stable due to continued pre-specified analyses expected in late 2025. BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025.
Is It Worth Investing in Denali Therapeutics Inc (NASDAQ: DNLI) Right Now?
The stock has a 36-month beta value of 1.41. Opinions on the stock are mixed, with 13 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DNLI is 124.68M, and at present, short sellers hold a 5.99% of that float. On January 10, 2025, the average trading volume of DNLI was 855.58K shares.
DNLI’s Market Performance
The stock of Denali Therapeutics Inc (DNLI) has seen a 4.27% increase in the past week, with a -14.62% drop in the past month, and a -20.50% fall in the past quarter. The volatility ratio for the week is 6.79%, and the volatility levels for the past 30 days are at 5.12% for DNLI. The simple moving average for the last 20 days is -2.14% for DNLI stock, with a simple moving average of -8.00% for the last 200 days.
Analysts’ Opinion of DNLI
Many brokerage firms have already submitted their reports for DNLI stocks, with Robert W. Baird repeating the rating for DNLI by listing it as a “Outperform.” The predicted price for DNLI in the upcoming period, according to Robert W. Baird is $31 based on the research report published on January 07, 2025 of the current year 2025.
Stifel gave a rating of “Buy” to DNLI, setting the target price at $37 in the report published on December 16th of the previous year.
DNLI Trading at -13.40% from the 50-Day Moving Average
After a stumble in the market that brought DNLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.24% of loss for the given period.
Volatility was left at 5.12%, however, over the last 30 days, the volatility rate increased by 6.79%, as shares sank -14.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.74% lower at present.
During the last 5 trading sessions, DNLI rose by +4.27%, which changed the moving average for the period of 200-days by +8.31% in comparison to the 20-day moving average, which settled at $21.71. In addition, Denali Therapeutics Inc saw 4.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNLI starting from Ho Carole, who sale 12,255 shares at the price of $20.22 back on Jan 06 ’25. After this action, Ho Carole now owns 178,580 shares of Denali Therapeutics Inc, valued at $247,796 using the latest closing price.
Ho Carole, the Chief Medical Officer of Denali Therapeutics Inc, sale 2,907 shares at $20.81 during a trade that took place back on Jan 07 ’25, which means that Ho Carole is holding 175,673 shares at $60,495 based on the most recent closing price.
Stock Fundamentals for DNLI
Current profitability levels for the company are sitting at:
- 1.65 for the present operating margin
- 1.02 for the gross margin
The net margin for Denali Therapeutics Inc stands at 1.4. The total capital return value is set at -0.37. Equity return is now at value -35.09, with -31.77 for asset returns.
Based on Denali Therapeutics Inc (DNLI), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -45.13. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -23.94.
Currently, EBITDA for the company is -179.97 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of -9.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.98.
Conclusion
To sum up, Denali Therapeutics Inc (DNLI) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
